Long-term follow-up in an open-label trial of triheptanoin in GLUT1 deficiency syndrome: a sustained dramatic effect

Elodie Hainque, Domitille Gras, Aurélie Meneret, Mariana Atencio, Marie-Pierre Luton, Magali Barbier, Mohamed Doulazmi, Florence Habarou, Chris Ottolenghi, Emmanuel Roze, Fanny Mochel, Elodie Hainque, Domitille Gras, Aurélie Meneret, Mariana Atencio, Marie-Pierre Luton, Magali Barbier, Mohamed Doulazmi, Florence Habarou, Chris Ottolenghi, Emmanuel Roze, Fanny Mochel

No abstract available

Keywords: GLUT1 deficiency syndrome; movement disorders; triheptanoin.

Conflict of interest statement

Competing interests: FM holds a patent on the use of triheptanoin in GLUT1-DS (WO2014093901).

Figures

Figure 1
Figure 1
(A) Flow chart. (B) Normalised number of paroxysmal events in patients with glucose transporter type 1 deficiency syndrome (GLUT1-DS) during the different phases of the study. Total and motor numbers of paroxysmal events are expressed in mean per month. Error bars represent SEM. *P

References

    1. De Vivo DC, Trifiletti RR, Jacobson RI, et al. . Defective glucose transport across the blood-brain barrier as a cause of persistent hypoglycorrhachia, seizures, and developmental delay. N Engl J Med 1991;325:703–9. 10.1056/NEJM199109053251006
    1. Leen WG, Klepper J, Verbeek MM, et al. . Glucose transporter-1 deficiency syndrome: the expanding clinical and genetic spectrum of a treatable disorder. Brain 2010;133:655–70. 10.1093/brain/awp336
    1. Alter AS, Engelstad K, Hinton VJ, et al. . Long-term clinical course of GLUT1 deficiency syndrome. J Child Neurol 2015;30:160–9. 10.1177/0883073814531822
    1. Pons R, Collins A, Rotstein M, et al. . The spectrum of movement disorders in GLUT-1 deficiency. Mov Disord 2010;25:275–81. 10.1002/mds.22808
    1. Klepper J, Leiendecker B. GLUT1 deficiency syndrome and novel ketogenic diets. J Child Neurol 2013;28:1045–8. 10.1177/0883073813487600
    1. Mochel F, DeLonlay P, Touati G, et al. . Pyruvate carboxylase deficiency: clinical and biochemical response to anaplerotic diet therapy. Mol Genet Metab 2005;84:305–12. 10.1016/j.ymgme.2004.09.007
    1. Adanyeguh IM, Rinaldi D, Henry P-G, et al. . Triheptanoin improves brain energy metabolism in patients with Huntington disease. Neurology 2015;84:490–5. 10.1212/WNL.0000000000001214
    1. Pascual JM, Liu P, Mao D, et al. . Triheptanoin for glucose transporter type I deficiency (G1D): modulation of human ictogenesis, cerebral metabolic rate, and cognitive indices by a food supplement. JAMA Neurol 2014;71:1255–65. 10.1001/jamaneurol.2014.1584
    1. Mochel F, Hainque E, Gras D, et al. . Triheptanoin dramatically reduces paroxysmal motor disorder in patients with GLUT1 deficiency. J Neurol Neurosurg Psychiatry 2016;87:550–3. 10.1136/jnnp-2015-311475
    1. Mochel F. Triheptanoin for the treatment of brain energy deficit: a 14-year experience. J Neurosci Res 2017;95:2236–43. 10.1002/jnr.24111

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera